NewsPronto

 
Men's Weekly

.

ACN Newswire

Read more press releases from ACN Newswire here

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

  • Written by ACN Newswire

image

TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.

On the basis of this agreement, the...

Read more: Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613,...